Alisertib - Takeda Oncology

Drug Profile

Alisertib - Takeda Oncology

Alternative Names: Alsertib; MLN-8237

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Fox Chase Cancer Center; Massachusetts General Hospital; Mayo Clinic; Millennium; National Cancer Institute (USA); Ohio State University Comprehensive Cancer Center; Takeda Oncology; UNC Lineberger Comprehensive Cancer Center; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine; Weill Cornell Medical College; Yale University School of Medicine
  • Class 3-ring heterocyclic compounds; Antineoplastics; Azepines; Benzazepines; Benzoic acids; Fluorobenzenes; Phenyl ethers; Pyrimidines; Small molecules
  • Mechanism of Action Aurora kinase A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; B cell lymphoma; Brain cancer; Breast cancer; Mesothelioma; Prostate cancer; Small cell lung cancer
  • Phase I/II Gynaecological cancer; Non-small cell lung cancer; Solid tumours
  • Phase I Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Gastric cancer; Oesophageal cancer
  • Preclinical Head and neck cancer
  • No development reported Cancer; Lymphoma; Non-Hodgkin's lymphoma
  • Discontinued Myelodysplastic syndromes; Ovarian cancer; Peripheral T-cell lymphoma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO, Capsule)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cancer in Japan (PO, Capsule)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cancer in Spain (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top